Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.74 |
| ▸ | CTSK | P43235 | 11/20 | 0.74 |
| ▸ | CTSB | P07858 | 4/20 | 0.74 |
| ▸ | CTSL | P07711 | 2/20 | 0.74 |
| ▸ | AKT1 | P31749 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465196 | 1.00 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10767107 | 0.98 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2793925 | 0.91 | CTSS (0.76) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1001781 | 0.91 | CTSS (0.76) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL12706400 | 0.90 | BCL2 (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL12826514 | 0.90 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL30279290 | 0.90 | REN (0.63) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL28916808 | 0.90 | REN (0.63) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18154315 | 0.89 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10456411 | 0.89 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200370057-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200370057-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | CTSS 2862/4885CTSK 2200/4885CTSB 2609/4885 |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | CTSS 3436/4885CTSK 3609/4885CTSB 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.